European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

MT Newswires Live
05-12

European equities traded in the US as American depositary receipts were tracking higher late Monday morning, rising 0.24% to 1,407.61 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical company DBV Technologies (DBVT) and accommodations booking site trivago (TRVG), which climbed 10% and 5.1%, respectively. They were followed by biotech firm Evaxion Biotech (EVAX) and internet browser company Opera (OPRA), which rose 4.7% and 3.8%, respectively.

The decliners from continental Europe were led by biopharmaceutical company Cellectis (CLLS) and medical device maker EDAP TMS (EDAP), which dropped 7.7% and 4.7%, respectively. They were followed by telecommunications operator Telefonica (TEF) and pharmaceutical company Novo Nordisk (NVO), which were down 3.1% and 1.7%, respectively.

From the UK and Ireland, the gainers were led by biotech firm Autolus Therapeutics (AUTL) and cruise line operator Carnival (CUK), which advanced 9.1% and 8.5%, respectively. They were followed by biopharmaceutical company Adaptimmune Therapeutics (ADAP) and pharmaceutical company Silence Therapeutics (SLN), which were up 5.3% and 4.9%, respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and utilities company National Grid (NGG), which fell 12% and 4.2%, respectively. They were followed by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company NuCana (NCNA), which lost 2.3% and 1.7%, respectively.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10